Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Operating Leases (2022 - 2025)

Candel Therapeutics' Operating Leases history spans 2 years, with the latest figure at $973000.0 for Q4 2023.

  • On a quarterly basis, Operating Leases fell 34.52% to $973000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $973000.0, a 34.52% decrease, with the full-year FY2023 number at $973000.0, down 34.52% from a year prior.
  • Operating Leases hit $973000.0 in Q4 2023 for Candel Therapeutics, down from $1.1 million in the prior quarter.
  • Over the last five years, Operating Leases for CADL hit a ceiling of $1.8 million in Q1 2022 and a floor of $973000.0 in Q4 2023.